Applied Therapeutics Inc.(APLT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APLT Applied Therapeutics Inc.

Closed Good Friday 04-17 16:00:00 EDT

0.3330

+0.0292

+9.61%

盘后0.3420

+0.0090+2.70%

19:16 EDT

High0.3463	Low0.3121	Vol1.78M
Open0.3121	D1 Closing0.3038	Amplitude11.26%
Mkt Cap47.14M	Tradable Cap32.30M	Total Shares141.58M
T/O593.94K	T/O Rate1.84%	Tradable Shares97.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"APLT","market":"US","secType":"STK","nameCN":"Applied Therapeutics Inc.","latestPrice":0.333,"timestamp":1744920000000,"preClose":0.3038,"halted":0,"volume":1784961,"hourTrading":{"tag":"盘后","latestPrice":0.342,"preClose":0.333,"latestTime":"19:16 EDT","volume":31832,"amount":10711.6463,"timestamp":1744931779679},"delay":0,"floatShares":96999000,"shares":141575526,"eps":-0.76,"marketStatus":"Closed Good Friday","change":0.0292,"latestTime":"04-17 16:00:00 EDT","open":0.3121,"high":0.3463,"low":0.3121,"amount":593943.987789,"amplitude":0.112574,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.76,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1557806400000,"exchange":"NASDAQ","adjPreClose":0.3038,"preHourTrading":{"tag":"盘前","latestPrice":0.327,"preClose":0.3038,"latestTime":"09:29 EDT","volume":6787,"amount":2166.5088115,"timestamp":1744896579183},"postHourTrading":{"tag":"盘后","latestPrice":0.342,"preClose":0.333,"latestTime":"19:16 EDT","volume":31832,"amount":10711.6463,"timestamp":1744931779679},"volumeRatio":0.9337138644497393,"impliedVol":1.1669,"impliedVolPercentile":0.2709},"requestUrl":"/m/hq/s/APLT","defaultTab":"news","newsList":[{"id":"2527469983","title":"William Blair Sticks to Its Hold Rating for Applied Therapeutics (APLT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527469983","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527469983?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 17:17","pubTimestamp":1744708672,"startTime":"0","endTime":"0","summary":"William Blair analyst Sami Corwin maintained a Hold rating on Applied Therapeutics (APLT – Research Report) today. The company’s shares closed yest...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-sticks-to-its-hold-rating-for-applied-therapeutics-aplt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-sticks-to-its-hold-rating-for-applied-therapeutics-aplt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APLT"],"gpt_icon":0},{"id":"2527012818","title":"Press Release: Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2527012818","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527012818?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 05:50","pubTimestamp":1744667400,"startTime":"0","endTime":"0","summary":"-  Appointed John H. Johnson as Executive Chairman; Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer; and Reena Thomas Colacot as Vice President and Head of Quality. NEW YORK, April 14, 2025  -- Applied Therapeutics, Inc.  , a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the fourth quarter and full year ended December 31, 2024.\"We remain focused on preparing for potential regulatory interactions regarding govorestat in both Classic Galactosemia and Sorbitol Dehydrogenase  Deficiency,\" said Les Funtleyder, Interim CEO and CFO of Applied Therapeutics. \"As we continue to optimize our strategy for our late-stage programs, we have also made key senior appointments across regulatory, medical and quality affairs functions to bolster our capabilities. We are confident in the promise of govorestat across indications and remain com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLT","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","LENZ","BK4139","BK4007"],"gpt_icon":1},{"id":"2526656353","title":"North American Morning Briefing: China Raises Tariffs on U.S. in Latest Salvo","url":"https://stock-news.laohu8.com/highlight/detail?id=2526656353","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526656353?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 18:01","pubTimestamp":1744365660,"startTime":"0","endTime":"0","summary":"Stock futures edged higher despite the trade war between the world's largest economies spiraled further Friday, with China lifting tariffs on the U.S . to 125% and scoffing that further U.S. levies would be seen around the globe as a \"joke.\". China said it wouldn't continue to match any levy increases by the U.S.\"Even if the U.S. continues to impose higher tariffs, it would be economically meaningless and would become a joke in the history of the world economy,\" China said.Chinese leader Xi Jinping said that if the showdown continued, his country \"is not afraid.\". The partial suspension of U.S. tariffs \"remains fragile,\"  and the European Union must continue to prepare counter-measures to defend itself, French President Emmanuel Macron said earlier Friday.BlackRock was up 0.7. Analysts expect BlackRock's assets under management during the first quarter to reach a record of $11.69 trillion, up from $10.47 trillion a year earlier.JPMorgan Chase is expected by Wall Street to report first-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a205a489ab00abbcdcfe94a2c4c57263","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0005OL40V9.USD","LU1814569148.SGD","LU0348723411.USD","LU2360106780.USD","ADVM","LU1791710582.SGD","BK4554","PLCE","LU1506573853.SGD","IE00BGHQF748.EUR","AFG","LU2347655156.SGD","LU2361044865.SGD","LU1244550494.USD","BLK","LU0072462426.USD","LU1244550221.USD","ET","LU0784384876.USD","CEIN","LU0823434583.USD","MACW.SI","LU0444971666.USD","LU0256863811.USD","SG9999002232.USD","LU0466842654.USD","BEEM","LU2111349929.HKD","LU2028103732.USD","LU1989772840.SGD","BK4170","BK4592","LU2456880835.USD","LU2237443382.USD","LU1366333091.USD","AREN","BK","CCNE","LU0056508442.USD","BK4182","LU0724617625.USD","IE00B19Z8W00.USD","LU1037948897.HKD","APLT","LU0098860793.USD","LU0661504455.SGD","LU1934455194.USD","SG9999001424.SGD","SG9999014542.SGD"],"gpt_icon":1},{"id":"2523991075","title":"Applied Therapeutics files Form 12b-25 with SEC","url":"https://stock-news.laohu8.com/highlight/detail?id=2523991075","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523991075?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:20","pubTimestamp":1743420057,"startTime":"0","endTime":"0","summary":"Applied Therapeutics (APLT) has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission related to the C...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/applied-therapeutics-files-form-12b-25-with-sec?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/applied-therapeutics-files-form-12b-25-with-sec?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","LU0109394709.USD","LENZ","LU0320765992.SGD","APLT","BK4139"],"gpt_icon":0},{"id":"2520090268","title":"Applied Therapeutics appoints Baumgartner as Chief Regulatory Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520090268","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520090268?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 19:16","pubTimestamp":1742383018,"startTime":"0","endTime":"0","summary":"Applied Therapeutics (APLT) announced the appointment of Todd Baumgartner, MD, MPH as Chief Regulatory Officer. Dr. Baumgartner will serve as part ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/applied-therapeutics-appoints-baumgartner-as-chief-regulatory-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/applied-therapeutics-appoints-baumgartner-as-chief-regulatory-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","LU0889565916.HKD","APLT","BK4139","LU0320765992.SGD","LENZ"],"gpt_icon":0},{"id":"2520909297","title":"Applied Therapeutics Appoints Todd F. Baumgartner, Md, Mph as Chief Regulatory Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520909297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520909297?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 19:00","pubTimestamp":1742382001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA7PDSRJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","APLT","LU0320765992.SGD","BK4139","LU0889565916.HKD"],"gpt_icon":0},{"id":"2520590943","title":"Press Release: Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520590943","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520590943?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 19:00","pubTimestamp":1742382000,"startTime":"0","endTime":"0","summary":"Dr. Baumgartner will advance Applied's preparation for upcoming regulatory interactions. NEW YORK, March 19, 2025  -- Applied Therapeutics, Inc. , a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer. Dr. Baumgartner will serve as part of the Company's executive leadership team and will be responsible for leading Applied's global regulatory strategy.Dr. Baumgartner joins Applied as an accomplished global drug development leader with over 35 years of experience in senior regulatory, clinical development, and medical affairs roles. He has held a diverse set of leadership roles over the course of his career, notably leading a total of 12 New Drug Applications and marketing authorizations through their approvals.\"We are delighted to welcome Todd to Applied as we continue to prepare for regulatory interactions regarding govorestat,\" said John H. Johnson, Execu","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4585","LENZ","APLT","TM","BK4196","03160","BK4139","ARI","BK4099","LU0320765992.SGD","MD","BK4604","LU0109394709.USD","BK4555","BK4588","BK4110"],"gpt_icon":0},{"id":"2513250080","title":"BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2513250080","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513250080?lang=en_us&edition=full_marsco","pubTime":"2025-02-21 16:24","pubTimestamp":1740126240,"startTime":"0","endTime":"0","summary":"BeiGene, Ltd.  shares ended the last trading session 3.2% higher at $244.20. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.5% gain over the past four weeks.The stock price rally can be attributed to positive investor mindset regarding the sales growth potential of its internally discovered oncology products, including Brukinsa  and Tevimbra . BeiGene has several other pipeline candidates that are being developed for treating various cancer indications.This company is expected to post quarterly loss of $0.80 per share in its upcoming report, which represents a year-over-year change of +77.3%. Revenues are expected to be $1.09 billion, up 71.5% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-onc-soars-3-2-082400824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONC","APLT","LU0320765992.SGD","BK4139","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2510818083","title":"BRIEF-Applied Therapeutics Inc - Receives Nasdaq Notice For Minimum Bid Price Non-Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2510818083","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510818083?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 05:34","pubTimestamp":1739223287,"startTime":"0","endTime":"0","summary":"BRIEF-Applied Therapeutics Inc - Receives Nasdaq Notice For Minimum Bid Price Non-ComplianceApplied Therapeutics Inc APLT.O:APPLIED THERAPEUTICS INC - RECEIVES NASDAQ NOTICE FOR MINIMUM BID PRICE NON-COMPLIANCESource text: [ID:n0000950170-25-017114]Further company coverage: APLT.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3P10X5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","APLT","LU0320765992.SGD","BK4139","LU0889565916.HKD"],"gpt_icon":0},{"id":"2510818758","title":"Applied Therapeutics Inc - Receives Nasdaq Notice for Minimum Bid Price Non-Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2510818758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510818758?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 05:33","pubTimestamp":1739223234,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3P10X5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","BK4139","LU0109394709.USD","LU0889565916.HKD","APLT"],"gpt_icon":0},{"id":"2505331229","title":"Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality","url":"https://stock-news.laohu8.com/highlight/detail?id=2505331229","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505331229?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 20:00","pubTimestamp":1737460804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nTUABV1MP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APLT","BK4139","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2501253229","title":"Here’s Why Applied Therapeutics, Inc. (NASDAQ:APLT) Is Among the Best Diabetes Stocks to Buy Under $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2501253229","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501253229?lang=en_us&edition=full_marsco","pubTime":"2025-01-06 22:13","pubTimestamp":1736172806,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10.In this article, we are going to take a look at where Applied Therapeutics, Inc.  stands against the other diabetes stocks.Global Growth and Innovation in Diabetes Care: The Rise of Continuous Glucose Monitors and AI Integration. About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income nations. Every year, diabetes directly causes 1.5 million deaths on average. Both the number of cases and the prevalence of diabetes have steadily increased during the last several decades. However, according to the International Diabetes Federation, there are currently 500 million people with diabetes globally, and that number is expected to rise by 25% by 2030 and 51% by 2045.According to the most recent KFF Health Tracking survey, 12% of adult Americans say they have used a GLP-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-applied-therapeutics-inc-nasdaq-141326761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","BK4159","BK4585","LU0889565916.HKD","IE00B3QW5Z07.USD","QID","LU0109394709.USD","PSQ","NVIW.SI","NDAQ","LU2210150020.SGD","APLT","IE00B64PRP62.GBP","QLD","LU2210149790.SGD","NQmain","CAGR","IE00BGHQF748.EUR","IE00BKPKM429.USD",".IXIC","TSYW.SI","BK4588","MNQmain","TQQQ","USAW.SI","BK4139","BK4112","LU2095319765.USD","SQQQ","LU0320765992.SGD"],"gpt_icon":1},{"id":"2493752719","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2493752719","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493752719?lang=en_us&edition=full_marsco","pubTime":"2024-12-23 21:10","pubTimestamp":1734959436,"startTime":"0","endTime":"0","summary":"iLearningEngines  shares tumbled 36% in recent Monday premarket activity after saying it voluntarily initiated Chapter 11 bankruptcy proceedings in the US on Friday.Mistras Group  shares fell 21%, erasing the previous session's slight gain.Lexicon Pharmaceuticals  stock was down 12% after saying Friday it received an expected US Food and Drug Administration's complete response letter to \"discontinue launch preparations for Zynquista and focus solely on its clinical development pipeline.\"Applied Therapeutics  stock fell 4.3% after William Blair downgraded it to market perform from outperform.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4123","LU0320765992.SGD","LXRX","IE00B66KJ199.SGD","IE00B7SZL793.SGD","AILE","IE0031619046.USD","BK4023","LU0889565916.HKD","MG","APLT","IE00B19Z4B17.USD","LU0109394709.USD","BK4139"],"gpt_icon":1},{"id":"2493699759","title":"William Blair Downgrades Applied Therapeutics to Market Perform From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2493699759","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493699759?lang=en_us&edition=full_marsco","pubTime":"2024-12-23 20:11","pubTimestamp":1734955900,"startTime":"0","endTime":"0","summary":"Applied Therapeutics (APLT) has an average rating of overweight and mean price target of $4.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","APLT"],"gpt_icon":0},{"id":"2493759186","title":"Applied Therapeutics Cut to Market Perform From Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2493759186","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493759186?lang=en_us&edition=full_marsco","pubTime":"2024-12-23 20:10","pubTimestamp":1734955800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APLT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 23, 2024 07:10 ET (12:10 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLT","LENZ"],"gpt_icon":0},{"id":"2493748737","title":"William Blair downgrades Applied Therapeutics (APLT) to a Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2493748737","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493748737?lang=en_us&edition=full_marsco","pubTime":"2024-12-23 18:15","pubTimestamp":1734948941,"startTime":"0","endTime":"0","summary":"Applied Therapeutics (APLT – Research Report) received a Hold rating and price target from William Blair analyst Sami Corwin today. The company’s s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-downgrades-applied-therapeutics-aplt-to-a-hold?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-downgrades-applied-therapeutics-aplt-to-a-hold?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APLT"],"gpt_icon":0},{"id":"2493408583","title":"Penny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2493408583","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493408583?lang=en_us&edition=full_marsco","pubTime":"2024-12-21 06:15","pubTimestamp":1734732951,"startTime":"0","endTime":"0","summary":"Adrian Alexandru, representing all similarly affected investors, has filed a federal securities class-action lawsuit against Applied Therapeutics , alleging the company violated federal securities laws.The lawsuit claims that the company provided misleading information about its clinical trials and failed to disclose key adverse facts, causing significant financial losses for shareholders.Also Read: Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside. The class action covers investors who purchased Applied Therapeutics securities between January 3, 2024, and December 2, 2024.Central to the lawsuit are claims that the company touted positive results from its Phase 3 INSPIRE trial for govorestat for Galactosemia, without disclosing significant issues. Bloomberg Law published a copy of the lawsuit online.Allegations include problems with electronic data capture and dosing errors during the dose-escalation phase of ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UajFcVXyBbGW._8YHZnAzA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/d3cae5694e766314b62be2ea5ce66552","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UajFcVXyBbGW._8YHZnAzA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/d3cae5694e766314b62be2ea5ce66552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/penny-stock-applied-therapeutics-fda-221551580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["APLT","LU0109394709.USD","CRL","BK4139","BK4530","LU0390134368.USD","LENZ","BK4121","LU0889565916.HKD","BK4585","LU0320765992.SGD","BK4588"],"gpt_icon":1},{"id":"2492527410","title":"Applied Therapeutics Names John Johnson as Executive Chair, Les Funtleyder as Interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2492527410","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492527410?lang=en_us&edition=full_marsco","pubTime":"2024-12-20 20:45","pubTimestamp":1734698734,"startTime":"0","endTime":"0","summary":"Applied Therapeutics (APLT) said it appointed John Johnson as executive chairman and Chief Financial Officer Les Funtleyder as interim chief executive, effective immediately.Johnson and Funtleyder suc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU0109394709.USD","APLT","LU0320765992.SGD","LENZ","LU0889565916.HKD"],"gpt_icon":1},{"id":"2492239417","title":"RBC Cuts Price Target on Applied Therapeutics to $1.50 From $4, Keeps Sector Perform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2492239417","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492239417?lang=en_us&edition=full_marsco","pubTime":"2024-12-20 20:40","pubTimestamp":1734698410,"startTime":"0","endTime":"0","summary":"Applied Therapeutics (APLT) has an average rating of overweight and mean price target of $4.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APLT","LENZ"],"gpt_icon":0},{"id":"2492417688","title":"Applied Therapeutics CEO Shendelman Steps Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2492417688","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492417688?lang=en_us&edition=full_marsco","pubTime":"2024-12-20 20:35","pubTimestamp":1734698100,"startTime":"0","endTime":"0","summary":"Applied Therapeutics Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO.Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson & Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position.\"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities,\" said Teena Lerner, Applied Therapeutics' lead independent director.Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","APLT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.appliedtherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0508},{"period":"1month","weight":-0.3605},{"period":"3month","weight":-0.49},{"period":"6month","weight":-0.9628},{"period":"1year","weight":-0.9311},{"period":"ytd","weight":-0.6111}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.049794},{"month":2,"riseRate":0.333333,"avgChangeRate":0.081838},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.084606},{"month":4,"riseRate":0.333333,"avgChangeRate":0.073628},{"month":5,"riseRate":0.4,"avgChangeRate":-0.046053},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.091706},{"month":7,"riseRate":0.666667,"avgChangeRate":0.074437},{"month":8,"riseRate":0.5,"avgChangeRate":0.019686},{"month":9,"riseRate":0.666667,"avgChangeRate":0.137906},{"month":10,"riseRate":0.333333,"avgChangeRate":0.000959},{"month":11,"riseRate":0.5,"avgChangeRate":-0.029191},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.0046}],"exchange":"NASDAQ","name":"Applied Therapeutics Inc.","nameEN":"Applied Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Applied Therapeutics Inc.(APLT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Applied Therapeutics Inc.(APLT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Applied Therapeutics Inc.,APLT,Applied Therapeutics Inc.股票,Applied Therapeutics Inc.股票老虎,Applied Therapeutics Inc.股票老虎国际,Applied Therapeutics Inc.行情,Applied Therapeutics Inc.股票行情,Applied Therapeutics Inc.股价,Applied Therapeutics Inc.股市,Applied Therapeutics Inc.股票价格,Applied Therapeutics Inc.股票交易,Applied Therapeutics Inc.股票购买,Applied Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Applied Therapeutics Inc.(APLT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Applied Therapeutics Inc.(APLT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction